Toru Aizawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Toru Aizawa has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Kiyoshi Hashizume
From the *Department of Internal Medicine, Chikuma‐Chuo Hospital, Chikuma, Japan†Department of Internal Medicine, Asama General Hospital, Saku, Japan‡Department of Internal Medicine, Nagano‐Chuo Hospital, Nagano, Japan§Department of Aging Medicine and Geriatrics∥Center for Medical Education, Shinshu University School of Medicine, Matsumoto, Japan
3 shared publications- Akihiro Sakurai
Department of Medical Genetics, Shinshu University School of Medicine
1 shared publication Hiroshi Saito
The Department of Second Internal Medicine, Shinshu University School of Medicine
1 shared publicationKeishi Yamauchi
From the *Department of Internal Medicine, Chikuma‐Chuo Hospital, Chikuma, Japan†Department of Internal Medicine, Asama General Hospital, Saku, Japan‡Department of Internal Medicine, Nagano‐Chuo Hospital, Nagano, Japan§Department of Aging Medicine and Geriatrics∥Center for Medical Education, Shinshu University School of Medicine, Matsumoto, Japan
1 shared publicationKiyoshi Kitano
The Department of Second Internal Medicine, Shinshu University School of Medicine
1 shared publicationKunihide Hiramatsu
The Department of Geriatrics, Endocrinology and Metabolism, Shinshu University School of Medicine
1 shared publication
Latest Publications
- 5 March 2007
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 55 (4) , 541-547
Development, Worsening, and Improvement of Diabetic Microangiopathy in Older People: Six‐Year Prospective Study of Patients Under Intensive Diabetes Control
OBJECTIVES: To examine retinopathy and nephropathy in elderly patients with diabetes mellitus (DM) under intensive multifactorial DM control. DESIGN: Six‐year interventional observation study. SETTING: Multicenter study including four hospitals. PARTICIPANTS: Four hundred thirteen elderly (≥65) patients with type 2 DM attending each hospital for 1 year or longer; those receiving hemodialysis or with uncured malignancy were excluded. MEASUREMENTS: Development, worsening, and improvement of retinopathy and nephropathy and respective risk factors. RESULTS: The mean baseline hemoglobin (HbA1c), blood pressure (BP), and total cholesterol were 6.8%, 137/74 mmHg, and 5.13 mmol/L, respectively. Retinopathy developed in 45 of 168 (27%) patients and, of 63 with nonproliferative retinopathy, worsened and improved in 11 (17%) and 23 (37%), respectively. Nephropathy developed in 53 of 227 (23%) patients and improved in 13 of 51 (25%) having it baseline. The mean change in glomerular filtration rate (ΔGFR, baseline GFR–GFR at the end of the study period) in those with nephropathy at baseline was 21.5 mL/min. HbA1c was related to development of retinopathy ( P =.001, odds ratio (OR)=1.91), and serum creatinine ( P =.03, OR=1.02), systolic BP (SBP) ( P =.03, OR=1.22), and prior stroke ( P =.005, OR=3.21) were related to development of nephropathy. In patients with nephropathy at baseline, SBP ( P =.03, Spearman's rho (ρ)=0.310), total cholesterol ( P =.01, ρ=0.361), and low‐density lipoprotein cholesterol ( P =.03, ρ=0.322) were correlated with ΔGFR. CONCLUSION: In elderly patients under intensive control for DM, the outcome of microangiopathy is favorable. Modifiable risk factors were hyperglycemia for development of retinopathy and hypertension and hypercholesterolemia for development or worsening of nephropathy; prior stroke was an unmodifiable risk factor for development of nephropathy.
- 5 March 2007
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 55 (4) , 541-547
Development, Worsening, and Improvement of Diabetic Microangiopathy in Older People: Six‐Year Prospective Study of Patients Under Intensive Diabetes Control
OBJECTIVES: To examine retinopathy and nephropathy in elderly patients with diabetes mellitus (DM) under intensive multifactorial DM control. DESIGN: Six‐year interventional observation study. SETTING: Multicenter study including four hospitals. PARTICIPANTS: Four hundred thirteen elderly (≥65) patients with type 2 DM attending each hospital for 1 year or longer; those receiving hemodialysis or with uncured malignancy were excluded. MEASUREMENTS: Development, worsening, and improvement of retinopathy and nephropathy and respective risk factors. RESULTS: The mean baseline hemoglobin (HbA1c), blood pressure (BP), and total cholesterol were 6.8%, 137/74 mmHg, and 5.13 mmol/L, respectively. Retinopathy developed in 45 of 168 (27%) patients and, of 63 with nonproliferative retinopathy, worsened and improved in 11 (17%) and 23 (37%), respectively. Nephropathy developed in 53 of 227 (23%) patients and improved in 13 of 51 (25%) having it baseline. The mean change in glomerular filtration rate (ΔGFR, baseline GFR–GFR at the end of the study period) in those with nephropathy at baseline was 21.5 mL/min. HbA1c was related to development of retinopathy ( P =.001, odds ratio (OR)=1.91), and serum creatinine ( P =.03, OR=1.02), systolic BP (SBP) ( P =.03, OR=1.22), and prior stroke ( P =.005, OR=3.21) were related to development of nephropathy. In patients with nephropathy at baseline, SBP ( P =.03, Spearman's rho (ρ)=0.310), total cholesterol ( P =.01, ρ=0.361), and low‐density lipoprotein cholesterol ( P =.03, ρ=0.322) were correlated with ΔGFR. CONCLUSION: In elderly patients under intensive control for DM, the outcome of microangiopathy is favorable. Modifiable risk factors were hyperglycemia for development of retinopathy and hypertension and hypercholesterolemia for development or worsening of nephropathy; prior stroke was an unmodifiable risk factor for development of nephropathy.
- 1 January 1997
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 313 (1) , 67-69
Alopecia Universalis With Remission During Pregnancy and Prednisolone Therapy
- 1 January 1997
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 313 (1) , 67-69
Alopecia Universalis With Remission During Pregnancy and Prednisolone Therapy
- 1 January 1994
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 33 (3) , 147-149
Acquired Amegakaryocytic Thrombocytopenic Purpura with Humoral Inhibitory Factor for Megakaryocyte Colony Formation.
A 67-year-old man with thrombocytopenia, and amegakaryocytic but otherwise normal bone marrow, was evaluated. Antibody against thrombocytes was negative and the half-life of thrombocytes was normal. In vitro clonal culture of the patient's bone marrow cells yielded no megakaryocyte colony with normal granulocyte-macrophage and erythroid colony formation. Megakaryocyte colony formation of the control bone marrow cells was significantly suppressed by the addition of the patient's serum to the culture, suggesting the existence of humoral inhibitory factor(s) for megakaryocyte colony formation. Therapeutic trials with plasma exchange, cyclosporine, prednisolone, and cyclosporine plus prednisolone were all unsuccessful, but serious bleeding has been absent.
- 1 January 1994
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 33 (3) , 147-149
Acquired Amegakaryocytic Thrombocytopenic Purpura with Humoral Inhibitory Factor for Megakaryocyte Colony Formation.
A 67-year-old man with thrombocytopenia, and amegakaryocytic but otherwise normal bone marrow, was evaluated. Antibody against thrombocytes was negative and the half-life of thrombocytes was normal. In vitro clonal culture of the patient's bone marrow cells yielded no megakaryocyte colony with normal granulocyte-macrophage and erythroid colony formation. Megakaryocyte colony formation of the control bone marrow cells was significantly suppressed by the addition of the patient's serum to the culture, suggesting the existence of humoral inhibitory factor(s) for megakaryocyte colony formation. Therapeutic trials with plasma exchange, cyclosporine, prednisolone, and cyclosporine plus prednisolone were all unsuccessful, but serious bleeding has been absent.